ICRM
FOLD

Insight Capital Research & Management’s Amicus Therapeutics FOLD Stock Holding History

Insight Capital Research & Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-248,383
Closed -$1.48M – 129
2014
Q3 		$1.48M Buy
+248,383
New +$1.3M 0.39% 81

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Insight Capital Research & Management's FOLD Position: Q4 2014 in Review

Insight Capital Research & Management sold out of Amicus Therapeutics (FOLD) in Q4 2014, closing a stake of 248,383 shares — an estimated $1.48M sold.

Insight Capital Research & Management first reported a position in FOLD in Q3 2014 and held it in 1 quarter. The position peaked at $1.48M in Q3 2014. 109 funds tracked by Wall St. Rank hold FOLD as of Q4 2014.

  • Insight Capital Research & Management reported no remaining Amicus Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Insight Capital Research & Management sold 248,383 Amicus Therapeutics shares in Q4 2014, an estimated $1.48M.
  • Insight Capital Research & Management first reported a position in Amicus Therapeutics in Q3 2014 and held it in 1 quarter.
  • Insight Capital Research & Management's Amicus Therapeutics position peaked at $1.48M in Q3 2014.
  • 109 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2014.

Based on Insight Capital Research & Management's 13F filing for Q4 2014, filed 10 Feb 2015.